March 3, 2023
Alfresa Holdings said on March 1 that its pharmaceutical subsidiary Alfresa Pharma has signed a licensing agreement with K Pharma, a biotech startup originating from Keio University, to develop and market ropinirole in Japan as an amyotrophic lateral sclerosis (ALS)...read more